Literature DB >> 25494650

CNS drug design: balancing physicochemical properties for optimal brain exposure.

Zoran Rankovic1.   

Abstract

The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins. Designing molecules that can overcome this protection system and achieve optimal concentration at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery. Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates. This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chemistry strategies toward molecules with optimal brain exposure. A summary of modern CNS pharmacokinetic concepts and methods is also provided.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25494650     DOI: 10.1021/jm501535r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  106 in total

1.  Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs.

Authors:  Hakan Gunaydin
Journal:  ACS Med Chem Lett       Date:  2015-12-02       Impact factor: 4.345

2.  Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.

Authors:  Xin Li; Zhigao Zhang; Yang Chen; Hong Wan; Jiakang Sun; Bin Wang; Bingqiang Feng; Bing Hu; Xingxing Shi; Jun Feng; Lei Zhang; Feng He; Chang Bai; Lianshan Zhang; Weikang Tao
Journal:  ACS Med Chem Lett       Date:  2019-05-29       Impact factor: 4.345

3.  Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.

Authors:  Ha T Do; Huiying Li; Georges Chreifi; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2019-02-25       Impact factor: 7.446

4.  Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

Authors:  Shefali Srivastava; Emily A Fergason-Cantrell; Roger I Nahas; John R Lever
Journal:  Tetrahedron       Date:  2016-08-04       Impact factor: 2.457

5.  Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.

Authors:  Julian R Levell; Thomas Caferro; Gregg Chenail; Ina Dix; Julia Dooley; Brant Firestone; Pascal D Fortin; John Giraldes; Ty Gould; Joseph D Growney; Michael D Jones; Raviraj Kulathila; Fallon Lin; Gang Liu; Arne Mueller; Simon van der Plas; Kelly Slocum; Troy Smith; Remi Terranova; B Barry Touré; Viraj Tyagi; Trixie Wagner; Xiaoling Xie; Ming Xu; Fan S Yang; Liping X Zhou; Raymond Pagliarini; Young Shin Cho
Journal:  ACS Med Chem Lett       Date:  2016-12-16       Impact factor: 4.345

6.  Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.

Authors:  Aaron M Bender; Nicholas W Griggs; Jessica P Anand; John R Traynor; Emily M Jutkiewicz; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2015-05-13       Impact factor: 4.418

Review 7.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

8.  Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

Authors:  Ingrid Buchler; Daniel Akuma; Vinh Au; Gregory Carr; Pablo de León; Michael DePasquale; Glen Ernst; Yifang Huang; Martha Kimos; Anna Kolobova; Michael Poslusney; Huijun Wei; Dominique Swinnen; Florian Montel; Florence Moureau; Emilie Jigorel; Monika-Sarah E D Schulze; Martyn Wood; James C Barrow
Journal:  J Med Chem       Date:  2018-10-19       Impact factor: 7.446

9.  Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice.

Authors:  Minjee Kim; Janice K Laramy; Afroz S Mohammad; Surabhi Talele; James Fisher; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-01-31       Impact factor: 3.922

10.  Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis.

Authors:  Chudi O Ndubaku; Terry D Crawford; Huifen Chen; Jason W Boggs; Joy Drobnick; Seth F Harris; Rajiv Jesudason; Erin McNamara; Jim Nonomiya; Amy Sambrone; Stephen Schmidt; Tanya Smyczek; Philip Vitorino; Lan Wang; Ping Wu; Stacey Yeung; Jinhua Chen; Kevin Chen; Charles Z Ding; Tao Wang; Zijin Xu; Stephen E Gould; Lesley J Murray; Weilan Ye
Journal:  ACS Med Chem Lett       Date:  2015-06-29       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.